Quality and regulatory compliance in fill-finish: the foundation for sterile injectable success

Sterile injectable (SI) therapies are growing more complex, and regulatory expectations for aseptic fill-finish have never been higher. From revised EU GMP Annex 1 requirements to the demands of mAbs, ADCs and peptides, drug developers face mounting pressure to maintain quality without slowing supply.

Pfizer CentreOne brings together advanced aseptic capabilities and Pfizer’s global manufacturing standards to support the safe, efficient and scalable delivery of your SI therapy.

In this eBook, you will learn:

How the revised Annex 1 reshapes contamination control and quality risk management
Strategies for protecting quality across increasingly complex SI modalities
What built-in risk frameworks, continuous investment and advanced technologies help support reliable supply

Download the eBook to build your foundation for excellence in every injection.

Pfizer CentreOne

Free Download

Fill out the form

Salutation First Name Last Name Email* Company Phone Department Position Street Zip City Country * Declaration of Consent

By completing this form to access the e-book, I understand my data will be shared with Pfizer CentreOne who may send me relevant updates and offers, and I can unsubscribe at any time via opt-out instructions in the emails. For more information on how your information will be used, please see the Privacy Policy.

Notes on data protection: Before receiving the whitepaper, you must register by providing your first and last name, your e-mail address, and possibly other data about yourself or your company. Please fill in the fields provided in the registration form.

Your data will be stored at B2B Expertise for the purpose of direct marketing and will be passed on to all affiliated companies of B2B Interactive GmbH as well as to our partner Pfizer CentreOne. For more information on the processing in our company, please refer to the B2B Interactive Privacy Policy.

You can revoke your consent at any time with effect for the future in writing by e-mail to the following address: info@b2binteractive.com (Subject: Pfizer CentreOne).